Aptar Pharma announced that it has acquired nasal delivery technology from Israeli nasal drug developer SipNose Nasal Delivery Systems. In addition to developing devices, SipNose has a pipeline of candidates developed in-house and candidates in development with partners, such as Noveome’s ST266 secretome.
According to Aptar, the company has acquired all of SipNose’s assets related to the nasal device technology, which includes single- and multi-dose spray pumps for both liquids and powders. The announcement cites the ability of the SipNose devices to “offer the opportunity to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery.”
The announcement highlights the potential for new research and development created by adding to Aptar’s current portfolio of nasal delivery devices, which includes Unidose (UDS) devices for delivery of liquids and powders to the nose, as well as the Bidose (BDS) liquid pumps. Earlier this year, Aptar announced an expansion of manufacturing capacity for the UDS system.
Aptar Pharma Business Development Director Reenal Gandhi commented, “SipNose is focused on development and innovation in intranasal drug delivery. Integrating these assets into our portfolio underlines Aptar Pharma’s continued expansion into the nasal drug delivery space.”
Aptar Pharma Prescription President Alex Theodorakis said, “Our nasal systems’ proven capabilities have brought added value to our customers and further convenience for patients worldwide for over 30 years. As the nasal market looks to develop new drugs to address unmet patient needs, this transaction will enhance Aptar’s portfolio of nasal drug delivery systems with a focus on CNS diseases.”
Read the Aptar Pharma press release.
